Generic drug citizen petitions would apply only "prospectively" under Barr proposal.
Executive Summary
GENERIC DRUG CITIZEN PETITIONS WOULD NOT AFFECT PENDING ANDAs UNDER BARR PROPOSAL outlined by Barr Labs CEO Bruce Downey at a May 21 meeting of the Food & Drug Law Institute in Washington, D.C. In order for a "change in existing standards to apply to a pending application," Downey said, FDA would have to meet "the same standard as for withdrawing products from the market." The Generic Pharmaceutical Industry Association said it supports Downey's proposal.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth